Beyond inhibition: harnessing the DRD2-VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Current anti-angiogenic therapies targeting VEGF-A/VEGFR2 lack dynamic biomarkers for patient selection and dosing optimization, leading to suboptimal outcomes and toxicity.
• A critical need exists for precision biomarkers to guide anti-angiogenic treatment strategies.

Purpose of the Study:

• To propose a paradigm shift in anti-angiogenic therapy by leveraging the dopamine D2 receptor (DRD2)/VEGF-A paracrine feedback loop.
• To establish a theranostic platform for real-time assessment of tumor VEGF-dependency and rational treatment selection.

Main Methods:

• Investigating the role of VEGF-A in inducing endothelial DRD2 expression in the tumor microenvironment.
• Utilizing FDA-approved DRD2 agonists as functional probes for a dopaminergic challenge.
• Employing dynamic imaging to identify windows of maximal VEGF-dependency.

Main Results:

• VEGF-A selectively induces endothelial DRD2 expression via transcriptional mechanisms, a signature absent in normal vasculature.
• DRD2 activation acts as a tumor-specific vascular brake, inhibiting VEGFR2 phosphorylation and paracellular permeability.
• The dopaminergic challenge enables identification of maximal VEGF-dependency through dynamic imaging.

Conclusions:

• The DRD2/VEGF-A feedback loop offers a tumor-specific mechanism to regulate tumor vasculature.
• This approach transforms anti-angiogenic therapy into a precision theranostic platform.
• Real-time assessment of tumor VEGF-dependency allows for maximized efficacy and minimized toxicity in anti-angiogenic treatments.